RE: Presentation13 Jan 2025 11:19
Licensing deals
The company is actively pursuing global licensing agreements, riding the wave of a growing trend in the biopharma industry. According to recent trends, immunology and autoimmune drug assets are in high demand, with eleven deals exceeding $1 billion in the sector from 2023 to late September 2024.